| Christopher Ryan Easterling, MD | |
|
1339 East St Ste 420, Graham, TX 76450-4228 | |
| (940) 521-5500 | |
| (940) 521-5511 |
| Full Name | Christopher Ryan Easterling |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 1339 East St Ste 420, Graham, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538554134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R2322 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beyondfaith Homecare & Rehab Of Graham Llc | Graham, TX | Home health agency |
| Young County Home Health Care | Graham, TX | Home health agency |
| Kindred At Home | Grapevine, TX | Home health agency |
| Beyondfaith Hospice Llc | Graham, TX | Hospice |
| Graham Regional Medical Center | Graham, TX | Hospital |
| Faith Community Hospital | Jacksboro, TX | Hospital |
| Medical City Weatherford | Weatherford, TX | Hospital |
| Graham Oaks Care Center | Graham, TX | Nursing home |
| Garden Terrace Healthcare Center | Graham, TX | Nursing home |
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
For the majority of older, early-stage breast cancer patients, radiation therapy following breast conserving surgery may help prevent the need for a later mastectomy, according to research from The University of Texas MD Anderson Cancer Center.
CTBC Bank (USA) and its parent company CTBC Financial Holdings have donated $200,000 as a global partner to the Huntsman Cancer Foundation, which kicks off its new annual Championship for Cancer Research fundraiser.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed the first synthetic compound that can reverse the effects of a serious metabolic condition known as fatty liver disease. True to its name, the disease involves an abnormal buildup of fat in the liver.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 3 days ago
| Entity Name | C Ryan Easterling Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477045292 PECOS PAC ID: 7810245321 Enrollment ID: O20180731001844 |
News Archive
For the majority of older, early-stage breast cancer patients, radiation therapy following breast conserving surgery may help prevent the need for a later mastectomy, according to research from The University of Texas MD Anderson Cancer Center.
CTBC Bank (USA) and its parent company CTBC Financial Holdings have donated $200,000 as a global partner to the Huntsman Cancer Foundation, which kicks off its new annual Championship for Cancer Research fundraiser.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed the first synthetic compound that can reverse the effects of a serious metabolic condition known as fatty liver disease. True to its name, the disease involves an abnormal buildup of fat in the liver.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Ryan Easterling, MD 1339 East St, Graham, TX 76450-4228 Ph: (940) 521-5500 | Christopher Ryan Easterling, MD 1339 East St Ste 420, Graham, TX 76450-4228 Ph: (940) 521-5500 |
News Archive
For the majority of older, early-stage breast cancer patients, radiation therapy following breast conserving surgery may help prevent the need for a later mastectomy, according to research from The University of Texas MD Anderson Cancer Center.
CTBC Bank (USA) and its parent company CTBC Financial Holdings have donated $200,000 as a global partner to the Huntsman Cancer Foundation, which kicks off its new annual Championship for Cancer Research fundraiser.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed the first synthetic compound that can reverse the effects of a serious metabolic condition known as fatty liver disease. True to its name, the disease involves an abnormal buildup of fat in the liver.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 3 days ago
Dr. Jeffrey K Gilbertson, M.D. P.A. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1804 State Highway 16 S, Graham, TX 76450 Phone: 940-549-0039 Fax: 940-549-0073 | |
John F Lucas Iii, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1339 East St, Graham, TX 76450 Phone: 940-521-5500 Fax: 940-521-5511 | |
Hal D Huffman, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1339 East St, Graham, TX 76450 Phone: 940-521-5500 Fax: 940-521-5511 | |
Michael Castillo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1339 East St, Graham, TX 76450 Phone: 940-521-5500 | |
Steven Kent Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1339 East St, Graham, TX 76450 Phone: 940-521-5500 Fax: 940-521-5511 | |
Peter S Brown, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 820 Montgomery Rd Ste 202, Graham, TX 76450 Phone: 940-549-7741 Fax: 855-615-3435 |